益肺宣肺降浊胶囊治疗轻中度血管性痴呆的临床疗效观察

Observation of the Clinical Efficacy on Yifei Xuanfei Jiangzhuo Capsule in the Treatment of Mild-to-moderate Vascular Dementia

目的观察益肺宣肺降浊胶囊治疗轻中度血管性痴呆(VD)的临床疗效及安全性。方法采用随机双盲对照试验的设计方法,将80例患者分为益肺宣肺降浊胶囊治疗组(治疗组,40例)和吡拉西坦胶囊对照组(对照组,40例),观察治疗前后两组患者中医证候疗效、中医证候积分(SDSVD)、洛文斯顿作业疗法评定(LOTCA评定)、日常生活活动能力量表(ADL)的变化以及该药物的安全性。结果治疗后治疗组中医证候疗效改善优于对照组(P<0.05);治疗后2组患者SDSVD、LOTCA评定及ADL变化均较治疗前明显改善(P<0.05),治疗组较对照组改善更为明显(P<0.05),且无明显不良反应。结论益肺宣肺降浊胶囊能有效地改善VD患者的SDSVD、LOTCA评定及ADL,有肯定的临床疗效,且安全可靠,值得临床推广应用及进一步深化研究。

Objective Observation of the clinical therapeutic effect of Yifei Xuanfei Jiangzhuo Capsule on mild-to-moderate vascular dementia to explore its the degree of reaction of chemotherapy. Methods Eighty patients with mild-to-moderate vascular dementia were randomly divided into treatment group and control group with randomized-double blind and controlled design method , each group for 40 cases,respectively. The treatment group was accepted Yifei Xuanfei Jiangzhuo Capsule,while the control group was accepted Piracetam by oral. The changes such as the curative effect of TCM syndrome,The syndroms integral of TCM symptom （SDSVD）,Loewenstein Occupational Therapy Cognitive Assessment（LOTCA）,The daily living ability（ADL）,and The safety of the drug were observed. Results The curative effect of TCM syndrome,SDSVD、LOTCA,and ADL in 2 groups above were both signi cantly higher than those before treatment（P〈0.05）,with the treatment group being more obvious than the control group（P〈0.05）. Conclusion Yifei Xuanfei Jiangzhuo Capsule could effectively improve the SDSVD、LOTCA,and the curative effect of TCM syndrome on patients with mild-to-moderate vascular dementia,It obtains definite curative effect,and deserves to be spread and is studied further in the clinic.